Academics said the findings suggested there were multiple ways the drug could benefit the heart, rather than the protective effect achieved solely by weight loss alone
According to the SmPC approved by the MHRA, nausea and diarrhoea are very common (affecting more than 1 in 10 people), whilst vomiting, dyspepsia, and abdominal pain are common (affecting up to 1 in 10 people)
Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, et al
Tirzepatide is a medication that belongs to a class of drugs known as GLP-1 receptor agonists
[1] [2] Estos medicamentos funcionan imitando hormonas intestinales naturales que regulan el apetito y la glucosa